The precision diagnostics company BillionToOne based in Menlo Park (CA) raised $130M Series D funding, valued at over $1B.
The round was led Premji Invest with participation from Neuberger Berman and other incoming investors. Existing investors included Adam Street Partners, Baillie Gifford Hummingbird Ventures Civilization Ventures Libertus Capital and Fifty Years. Akshay Rai will join BillionToOne’s Board of Directors. He led the Series D funding round.
The company plans to use the money to expand its prenatal and cancer businesses.
BillionToOne, a precision diagnostics firm, has patented Quantitative counting Technology(tm). This multiplex technology can count DNA molecules down to the single molecule level. Northstar Select(r), and Northstar Response (r), are complementary liquid biopsy products that help clinicians select the best therapies and monitor patient responses, especially in late-stage cancer. Northstar Select(r), a ctDNA methylation assay, has a limit of detection that is 2-5x lower than other assays available on the market. Northstar Response(r), a ctDNA methylation assay, has a precision 10x greater than SNV assays.
BillionToOne has tested over 500K patients to date. The company’s ARR has grown from $0M in the first 4 years to $125M today.
FinSMEs
22/06/2024